Related Experiment Video
Updated: Aug 18, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
DNA-binding proteins in the sera of patients with malignant melanoma
Abstract:
Sera of patients with various malignancies are known to contain DNA-binding proteins (DBP) which are not present in sera of normal individuals. In this paper sera of patients with malignant melanoma (MM) were examined as to whether characteristic DBP are present, too. DBP are isolated by DNA-affinity chromatography and represent 0.5-0.9% of all serum proteins. After separation of the DBP by SDS slab gel electrophoresis no typical DBP is detectable in sera of MM-patients. However, quantitative differences are found in sera of patients in the clinical stages I-III and/or tumor level 3-5: 1. All 9 sera of patients who had clinical signs of MM contain more DBP with molecular weight (mw) of 20,000-24,000 dalton than control sera. However, these DBP are only increased in 30% of the 22 sera from MM-patients who had clinical signs for 13-73 months after tumor excision. 2. All sera of the 10 MM-patients of whom sera were drawn twice after tumor excision at an interval of 7-46 months without clinical signs, showed a reduction of DBP with mw 30,000, 68,000, and 165,000.
More Related Videos
07:41A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
06:25Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
Published on: March 29, 2024
Related Concept Videos
The Intrinsic Apoptotic Pathway
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...